Stockscreener 앱 받기
2.17
5.85%
0.12
시간 외 거래:
2.19
0.02
+0.92%
전일 마감가:
$2.05
열려 있는:
$2.09
하루 거래량:
312.56K
Relative Volume:
1.01
시가총액:
$228.31M
수익:
$7.05M
순이익/손실:
$-30.43M
주가수익비율:
-5.7286
EPS:
-0.3788
순현금흐름:
$21.84M
1주 성능:
+4.33%
1개월 성능:
-1.36%
6개월 성능:
-3.56%
1년 성능:
+5.60%
1일 변동 폭
$2.03
$2.19
1주일 범위
$2.01
$2.19
52주 변동 폭
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
PRQR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.17 | 217.01M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
Live market analysis of ProQR Therapeutics N.V.Breakout Screener With Alert Based Timing - Newser
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50-Day Moving AverageTime to Sell? - MarketBeat
Ranking ProQR Therapeutics N.V. among high performing stocks via toolsTechnical Safety Zone Pattern Recognition - Newser
ProQR Therapeutics (PRQR) to Release Earnings on Thursday - MarketBeat
Real time breakdown of ProQR Therapeutics N.V. stock performanceSecure Entry Point Finder with Analysis - Newser
How high can ProQR Therapeutics N.V. stock goAI Trading Forecast Based on Big Data - Newser
Buy Signal for ProQR Therapeutics N.V. Stock Key Technical Indicators to WatchLow Risk Stock Trade Opportunity Analysis - Newser
ProQR Therapeutics' (PRQR) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Using Ichimoku Cloud for ProQR Therapeutics N.V. technicalsFast Entry Strategy with Price Prediction - Newser
Analyzing ProQR Therapeutics N.V. with risk reward ratio chartsFree Swing Trading Entry Point Signals - Newser
Is ProQR Therapeutics N.V. stock a growth or value playChart Pattern Recognition for Profit Timing - Newser
How to forecast ProQR Therapeutics N.V. trends using time seriesChart Confirmation Setup with ROI Signals - Newser
Can ProQR Therapeutics N.V. recover in the next quarterHigh Accuracy Trade Setup Identification - Newser
ProQR: Q2 Earnings Snapshot - Manistee News Advocate
How institutional ownership impacts ProQR Therapeutics N.V. stockFree Breakout Momentum Picks With Protection - Newser
ProQR Therapeutics shares rise 3.17% intraday after reporting a Q2 loss of $13.8 million, missing Wall Street expectations. - AInvest
ProQR Therapeutics Reports Q2 Earnings: $13.8mln Loss, $4.3mln Revenue - AInvest
Real time alert setup for ProQR Therapeutics N.V. performanceDeep Learning Stock Forecast for Investors - Newser
Published on: 2025-08-08 07:28:56 - Newser
Using economic indicators to assess ProQR Therapeutics N.V. potentialFree Growth Based Investment Plan Guidance - Newser
Statistical indicators supporting ProQR Therapeutics N.V.’s strengthFree Community Shared Smart Money Signals - Newser
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Therapeutics NV earnings missed by €0.04, revenue fell short of estimates - Investing.com
ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs - TipRanks
ProQR Announces Second Quarter 2025 Operating and Financial Resu - GuruFocus
ProQR Therapeutics Updates on AX-0810 Clinical Trial Submission and Financial Results for Q2 2025 - Quiver Quantitative
ProQR Announces Second Quarter 2025 Operating and Financial Results - GlobeNewswire
ProQR's RNA Editing Breakthrough: First Clinical Trial Launch, €120M War Chest, and Expanding Lilly Partnership - Stock Titan
Is ProQR Therapeutics N.V. stock ready for a breakoutProven Trading System with Consistent Gains - Newser
Why ProQR Therapeutics N.V. stock attracts strong analyst attentionStock Holding Strategy Long-Term Summary Sheet - Newser
ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday - Defense World
ProQR Therapeutics N.V. stock outlook for YEARFree Consistent Gain Investment Strategies - Newser
What to do if you’re stuck in ProQR Therapeutics N.V.Short-Term Profit Alert With Entry Forecast - Newser
Will breakout in ProQR Therapeutics N.V. lead to full recoveryConsistent Return Setup with Exit Strategy - Newser
ProQR Therapeutics N.V. Company Revenue and Profit Trends: A Deep DiveBuy and Hold Return Summary with Charts - Newser
Chart Analysts Warn of Resistance Near ProQR Therapeutics N.V. PriceBreakout Confirmation With Entry Tracker Enabled - metal.it
What makes ProQR Therapeutics N.V. stock price move sharplyROI Focused Setup Screener With Exit Markers - Newser
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):